Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial

Table 1 Baseline demographics

Parameter	Overall Population	PLA	PSE	P value¹
Age (years), Mean ± SD	27.5 ± 7.9	27.9 ± 7.8	27.2 ± 8.0	0.60
Race (n, %)				0.11
White	122 (86%)	55 (80%)	67 (92%)
Black or African American	11 (8%)	7 (10%)	4 (5%)
Asian	9 (6%)	7 (10%)	2 (3%)
Gender (n, %)				0.89
Male	98 (69%)	48 (70%)	50 (69%)
Female	44 (31%)	21 (30%)	23 (31%)
BMI (kg/m²), Mean ± SD	25.9 ± 3.2	25.8 ± 3.3	25.9 ± 3.2	0.86
Sleep (h)^a, Mean ± SD	7.2 ± 0.8	7.3 ± 0.8	7.2 ± 0.7	0.82
Exercise (h)^a, Mean ± SD	3.8 ± 2.0	3.8 ± 1.9	3.7 ± 2.0	0.66
New Zealand Physical Activity Questionnaire (h), Mean ± SD	4.7 ± 1.3	5.0 ± 1.2	4.44 ± 1.4	0.01

Abbreviations: BMI body mass index, PSE proprietary spearmint extract, PLA placebo, SD standard deviation
¹P value for PLA versus PSE calculated via Fisher’s exact test
^aData obtained from study diary collected for 7 days between phone screening and baseline visit

ISSN: 1550-2783